Welireg, Padcev, and a surprise fillip for Flare.
ApexOnco Front Page
Recent articles
Two new pivotal Chinese first-line trials have started in lung cancer.
The company’s AN9025 will shortly enter phase 1.
Deteriorating efficacy and a treatment-related death with Zynlonta plus Columvi spook investors.
Though lung cancer looks promising a partner is now needed.
A more comprehensive dataset on JANX007 sends the group’s stock down.
But the group still hopes to get IGV-001 approved based on overall survival data.
Car-T therapies and ADCs feature among recent first-in-human study entrants.
